The disclosure concerns a method for cancer treatment by in vivo priming and activation of natural killer cells for achieving tumor cell lysis. The method includes introducing into a patient a priming tumor cell preparation (PTCP) derived from a first tumor cell line, which is irradiated to inactivate the first tumor cells or a membrane preparation thereof, the first tumor cells having known priming ligands on the membrane surface thereof. The patient's rest NK cells are contacted by the PTCP in vivo, resulting in primed NK cells, which are characterized by upregulation of CD69, shedding of CD16, or a combination of CD69+ and CD16. These primed NK cells then contact second tumor cells, the cancer, and are configured to lyse and kill the second tumor cells.

Disclosed herein is a photochemical preparation method of an autologous plasma inactivated vaccine for the treatment of acquired immune deficiency syndrome (AIDS), including the following steps: drawing autologous blood from an AIDS patient to form blood to be treated; separating the blood to obtain plasma to be treated; adding a photosensitizer into the plasma to be treated to form plasma to be inactivated; and subjecting the plasma to be inactivated to photochemical inactivation to obtain the autologous plasma inactivated vaccine.

Disclosed herein is a photochemical preparation method of an autologous plasma inactivated vaccine for the treatment of acquired immune deficiency syndrome (AIDS), including the following steps: drawing autologous blood from an AIDS patient to form blood to be treated; separating the blood to obtain plasma to be treated; adding a photosensitizer into the plasma to be treated to form plasma to be inactivated; and subjecting the plasma to be inactivated to photochemical inactivation to obtain the autologous plasma inactivated vaccine.

A sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent; viral particles or a physiologically active polypeptide; an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and optionally, one or more sugars.

A sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent; viral particles or a physiologically active polypeptide; an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and optionally, one or more sugars.

The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye 700DX.

The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye 700DX.

Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. The subject methods include modifying donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.

An apparatus and method is provided for healing and regeneration of live human and animal bodies and influencing interaction and intercommunication at the cellular level. The apparatus can include one or more environmental and/or body sensors. An electrical circuit can also be provided to produce a square or trapezoidal wave that is delivered to a transducer for application, preferably timed at specific frequencies Delta, Theta, Alpha, to Beta, based on information received from the one or more sensors. In certain embodiments, a DC power source can be provided which allows the apparatus to be portable. A wireless communication module can also be provided. An apparatus and method for structuring water is also disclosed.

An apparatus and method is provided for healing and regeneration of live human and animal bodies and influencing interaction and intercommunication at the cellular level. The apparatus can include one or more environmental and/or body sensors. An electrical circuit can also be provided to produce a square or trapezoidal wave that is delivered to a transducer for application, preferably timed at specific frequencies Delta, Theta, Alpha, to Beta, based on information received from the one or more sensors. In certain embodiments, a DC power source can be provided which allows the apparatus to be portable. A wireless communication module can also be provided. An apparatus and method for structuring water is also disclosed.